

HRP Anti-Eg5 antibody [mAbcam 51976] α b202575

1 Image

Overview

Product name	HRP Anti-Eg5 antibody [mAbcam 51976]
Description	HRP Mouse monoclonal [mAbcam 51976] to Eg5
Host species	Mouse
Conjugation	HRP
Tested applications	Suitable for: WB
Species reactivity	Reacts with: Human
Immunogen	Synthetic peptide. This information is proprietary to Abcam and/or its suppliers.
Positive control	WB:HEK293, Jurkat and A431 whole cell lysates.
General notes	<p>The Life Science industry has been in the grips of a reproducibility crisis for a number of years. Abcam is leading the way in addressing this with our range of recombinant monoclonal antibodies and knockout edited cell lines for gold-standard validation. Please check that this product meets your needs before purchasing.</p> <p>If you have any questions, special requirements or concerns, please send us an inquiry and/or contact our Support team ahead of purchase. Recommended alternatives for this product can be found below, along with publications, customer reviews and Q&As</p>

Properties

Form	Liquid
Storage instructions	Shipped at 4°C. Store at +4°C short term (1-2 weeks). Upon delivery aliquot. Store at -20°C. Avoid freeze / thaw cycle. Store In the Dark.
Storage buffer	<p>pH: 7.40</p> <p>Preservative: 0.1% Proclin 300 Solution</p> <p>Constituents: PBS, 30% Glycerol (glycerin, glycerine), 1% BSA</p> <p>Note: Contains 0.4M Arginine</p>
Purity	IgG fraction
Clonality	Monoclonal
Clone number	mAbcam 51976
Myeloma	Sp2/0

Isotype

IgG1

Applications

The Abpromise guarantee

Our **Abpromise guarantee** covers the use of ab202575 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application	Abreviews	Notes
WB		1/5000. Detects a band of approximately 130 kDa (predicted molecular weight: 120 kDa).

Target

Function

Motor protein required for establishing a bipolar spindle. Blocking of KIF11 prevents centrosome migration and arrest cells in mitosis with monoastral microtubule arrays.

Involvement in disease

Defects in KIF11 are the cause of microcephaly with or without chorioretinopathy, lymphedema, or mental retardation (MCLMR) [MIM:152950]. An autosomal dominant disorder that involves an overlapping but variable spectrum of central nervous system and ocular developmental anomalies. Microcephaly ranges from mild to severe and is often associated with mild to moderate developmental delay and a characteristic facial phenotype with upslanting palpebral fissures, broad nose with rounded tip, long philtrum with thin upper lip, prominent chin, and prominent ears. Chorioretinopathy is the most common eye abnormality, but retinal folds, microphthalmia, and myopic and hypermetropic astigmatism have also been reported, and some individuals have no overt ocular phenotype. Congenital lymphedema, when present, is typically confined to the dorsa of the feet, and lymphoscintigraphy reveals the absence of radioactive isotope uptake from the webspaces between the toes.

Sequence similarities

Belongs to the kinesin-like protein family. BimC subfamily.
Contains 1 kinesin-motor domain.


Post-translational modifications

Phosphorylated exclusively on serine during S phase, but on both serine and Thr-926 during mitosis, so controlling the association of KIF11 with the spindle apparatus (probably during early prophase). Phosphorylated upon DNA damage, probably by ATM or ATR.
A subset of this protein primarily localized at the spindle pole is phosphorylated by NEK6 during mitosis; phosphorylation is required for mitotic function.

Cellular localization

Cytoplasm. Cytoplasm > cytoskeleton > spindle pole.

Images



All lanes : HRP Anti-Eg5 antibody [mAbcam 51976] (ab202575) at 1/5000 dilution

Lane 1 : HEK293 (Human embryonic kidney cell line) Whole Cell Lysate

Lane 2 : A431 (Human epithelial carcinoma cell line) Whole Cell Lysate

Lane 3 : Jurkat (Human T cell lymphoblast-like cell line) Whole Cell Lysate

Lysates/proteins at 10 µg per lane.

Developed using the ECL technique.

Performed under reducing conditions.

Predicted band size: 120 kDa

Observed band size: 130 kDa

Exposure time: 20 minutes

This blot was produced using a 4-12% Bis-tris gel under the MOPS buffer system. The gel was run at 200V for 50 minutes before being transferred onto a Nitrocellulose membrane at 30V for 70 minutes. The membrane was then blocked for an hour using 3% milk before being incubated with ab202575 overnight at 4°C. Antibody binding was visualised using ECL development solution [ab133406](#).

Please note: All products are "FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC PROCEDURES"

Our Abpromise to you: Quality guaranteed and expert technical support

- Replacement or refund for products not performing as stated on the datasheet
- Valid for 12 months from date of delivery
- Response to your inquiry within 24 hours
- We provide support in Chinese, English, French, German, Japanese and Spanish
- Extensive multi-media technical resources to help you
- We investigate all quality concerns to ensure our products perform to the highest standards

If the product does not perform as described on this datasheet, we will offer a refund or replacement. For full details of the Abpromise, please visit <https://www.abcam.com/abpromise> or contact our technical team.

Terms and conditions

- Guarantee only valid for products bought direct from Abcam or one of our authorized distributors